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Summary
Macrophages andcultured human monocytescan mediateefficient antibody-dependent cytotoxicity
(ADCC) against human tumor cells using monoclonal antibodies (mAbs). The mechanism of
this killing is usually assumed to involve secreted factors (reactive oxygen intermediates, tumor
necrosis factor, or other cytotoxic factors) leading to target cell lysis. In this study, we present
evidence that phagocytosis ofintact target cells is theprincipalmechanism of antitumorcytotoxicity
in ourin vitro modelof ADCCby cultured monocytes. Human monocytescultured in recombinant
human macrophage colony-stimulating factor ingested up to 100% of fluorochrome-labeled
melanoma and neuroblastoma target cells, in the presence of an appropriate antitumor mAb.
Electron microscopy demonstrated phagocytosis ofintact tumor cellsby cultured monocytes during
ADCC. All of the radionuclide in radiolabeled target cells was taken up by monocytes during
phagocytosis. By preventing the release of radioisotope tracers, phagocytosis thus prevents the
detection of this very efficient form of cytotoxicity by most conventional assays.
U
nder appropriate conditions, human monocytes are
capable of differentiating in vitro into large, metaboli-
cally active, macrophage-like cells (1, 2). We have recently
reported that such monocytes, cultured for 7-14 din human
serum or recombinant human macrophage CSF (rhM-CSF),'
mediate high levels of antibody-dependent cellular cytotox-
icity (ADCC) against human neuroblastoma andmelanoma
cell lines (3). At that time, we observed that several com-
monlyused isotope-releaseassays either significantly underes-
timatedor entirely failed to detect this efficientform ofADCC.
In this study, we investigate the hypothesis that phagocy-
tosis might be the mechanism of antitumor ADCC by cul-
tured monocytes, thus preventing release of radionuclide.
Cell Lines.
￿
Human tumor cell lines SKMel-1 (melanoma) and
SK-BR-3 (breast carcinoma) were obtained from theAmerican Type
CultureCollection, Rockville, MD. LA-N-1(neuroblastoma) was
the gift of Dr. Robert Seeger, UCLA, Los Angeles, CA. A431
(epidermoid carcinoma) was thegift ofDrs. HideoMasuiandJohn
Mendelsohn of Memorial Sloan-Kettering Cancer Center. LS180
(colon carcinoma) was obtained from Dr. DeborahYoung, Genetics
Institute, Cambridge, MA. Allcell lineswere propagated in RPMI
1640 (Gibco Laboratories, Grand Island, NY) supplemented with
' Abbreviations used in this paper. ADCC, antibody-dependent cellular
cytotoxicity; rhM-CSF, recombinant human macrophage CSF.
10% heat-inactivated bovine serum(HyClone Laboratories,Logan,
UT), 100 U/ml penicillin G, and 100 Ftg/ml streptomycin (BS-
RPMI). Cell linesused in theassays were always >90% viable by
trypan blue exclusion.
mAbs.
￿
ThemAb 3F8 (murine IgG3,anti-GD2) wasdeveloped
in ourlaboratory, and hasbeen previously described (4). Antibody
R24(murineIgG3, anti-GD3)wasthegift ofDr.Alan Houghton,
Memorial Sloan-Kettering Cancer Center. Antibody 528 (murine
IgG2a, anti-epidermal growth factor receptor) was the generous
gift of Drs. HideoMasui andJohn Mendelsohn, Memorial Sloan-
Kettering Cancer Center (5). NRC04 (murine IgG3, anti-colon
carcinoma) was the gift of NeoRxCorporation, Seattle, WA (6). A
mouse-human chimeric antibody ch14.18 (human IgG1 PC region,
anti-GD2), derived from the anti-GD2 murine monoclonal 14.18
(7-9), was the gift of Damon Biotech, Needham Heights, MA.
PE-conjugated anti-CD14 (Leu-M3) andanti-CD11b (Leu-15) were
purchased from Becton Dickinson & Co. (Mountain View, CA).
Cytokines.
￿
rhM-CSF (2 x 1( 6 U/mg) was generously supplied
by Genetics Institute. It was>99% pure by PAGE, and contained
<0.01 endotoxin units (EU)/ml at the working dilution used.
Separation and Culture ofPeripheral Blood Monocytes.
￿
Our mono-
cyte culture technique has been described previously (3). Briefly,
heparinized whole blood from normal volunteer donors was cen-
trifuged over Ficoll-Hypaque (Pharmacia Fine Chemicals, Pis-
cataway, NJ). The mononuclear cells were spun over acushion of
36% Percoll(Pharmacia Fine Chemicals) to remove platelets, then
enriched for monocytes by centrifugation over a single-step gra-
dient of 47% percoll. The interface layer (>95% of the monocyte
population, typically 40% pure) was suspendedin BS-RPMI (2-2.4
x 106 cells/ml, 100 /Al/well) and allowed to adhere to serum-
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plates were washed vigorously using a multichannel pipette. Ad-
herent cells (>95% monorytes by flow cytometry) were cultured
for 9-12 d in 150 pl of BS-RPMI medium supplemented with 200
U/ml rhM-CSF, with changes of medium as necessary. Cell counts
after culture were typically 3-5 x 10' cells per well; >95% were
monoryte/macrophages by morphology and flow cytometry. All
media and additives used in monocyte culture were screened for
endotoxin using a limulus amebocyte lysate assay (Associates of
Cape Cod, Woods Hole, MA) and contained <0.03 EU/ml in the
concentrations used.
Cytotoxicity Assay.
￿
Target cells (SKMel-1) were added directly
to the cultured monorytes, at 1 or 2 x 10' targets per well in 100
Pl of BS-RPMI (giving approximate E/T ratios of 4:1 and 2:1,
respectively). Antitumor antibody R24 was added at a final con-
centration of2 wg/ml. After0, 4, 8, and 24 h, thecells weredetached
with 2 mM EDTA (45 min at room temperature) and harvested
with vigorous pipetting. Target cells were stained with antitumor
antibody 3F8 F(ab')2 fragment biotin conjugate plus avidin-fluores-
cein. Monocytes were counterstained with a cocktail of PE-
conjugated antibodies (anti-CD14 plus anti-CDllb). The ratioof
residual target cells (3F8`, CD14/CD11b-) to effector cells (3F8-,
CD14/CDllb*) was determined by flow cytometry. This ratio was
converted into an actual number of target cells using the formula:
target cell number = (percent targets/percent effectors) x effector
cell number. Within a single experiment, we assumed that effector
cell number was constant for each sample, sinceone sample repre-
sented the average of 16 wells, and all wells were seeded and cul-
tured as identical replicates.
Radionuclide ReleaseAssays.
￿
Target cells (LA-N-1) were labeled
with either "Cr (100 UCi/106 cells) in 500 ul medium for 1 h,
or "'In (25 yCi/106 cells) in 1 ml medium for 15 min. Labeled
target cells were added to cultured monorytes along with 3F8
(2 lAg/ml) and incubated for 18 h at 37°C. The plates were cen-
trifuged, and 100 Al of supernatant was removed for gamma
counting. Radioactive medium was washed from the wells by three
cycles ofadding 200 P1 fresh medium, centrifuging, and removing
2001Al. This procedure was followed so that nonadherent cells would
not be disturbed. Residual targets were lysed with 200 141 human
complement serum (diluted 1 :2 in HBSS) plus excess 3F8 antibody
(10 Ag/ml) for 2 h at 37°C, and 100 Pl ofsupernatant was removed
for counting. Finally, the monocyte monolayer was washed free
ofresidual medium, the cells were lysedwith 250 Al of 0.1% triton
(Sigma Chemical Co., St. Louis, MO), and 100 Al was removed
for counting. Specific release was calculated as: 100x [(observed
release - spontaneous)/(total - spontaneous)]. Total release for
the 24-h ADCC assaywas determined by detergent lysis oflabeled
target cells. Spontaneous release during ADCC was 25-40% for
chromium and 5-10% for indium. Total release for the comple-
ment incubation was based on the maximum complement-releasable
counts from control target cells. Totalcomplement release was typi-
cally 80-85% of detergent-releasable counts; trypan blue dye
exclusion showed that >95% of tumor cells were dead after treat-
ment with complement. Spontaneous release during the comple-
ment lysis step was <5% .
PKH2 Labeling.
￿
Target cells were washed in PBS and labeled
with PKH2 dye (Zynaxis Cell Science, Malvern, PA) at 2 gM in
1 ml of the supplied diluent per 5 x 106 cells. The labeled cells
were washed three times and cultured overnight to reduce non-
specific leaking of dye during the assay. Target cells were 95-99%
viable after the leaking incubation. Labeled target cells were added
to rhM-CSF-cultured monorytes along with antitumor mAb (Nl-2
,ug/ml, depending on the antibody preparation), then harvested after
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0, 4, 8, or 24 h. Monocytes were counterstained with anti-CD14/anti-
CD11b PE as described above, and the cells analyzed by cytofluorom-
etry. The number of remaining target cells was calculated using the
formula: target cell number = [(percent targets + percent double posi-
tive)/(percent monocytes + percent double positive)] x effector cell
number. Target cells were defined as PKH2* and CD14/CD11b- .
Monocytes were defined as CD14/CDllb* and PKH2-. Double-
positive cells were counted as both a target cell and a monocyte.
Percent phagocytosis was calculated as: 100 x [percent double posi-
tive/(percent targets + percent double positive)]. To look for target
cells passively bound to monocytes without undergoing phagocy-
tosis, we viewed some of the experiments under epifluorescence
illumination in a hemacytometer. Any target cell found in close
apposition to a monoryte was scored as a possible conjugate.
Results
When cultured monorytes were incubated with tumor cells
in the presence of antitumor mAb, the number ofcells bearing
tumor-associated surface antigen declined rapidly (Fig. 1 A).
Two-color staining (Fig. 1 B) showed that antigen-positive
target cells were eliminated without the emergence of an
antigen-negative population. The ganglioside antigens used
in these assays were chosen, in part,because they showed little
modulation under the influence of antibody. Once all the
antigen-positive cells hadbeen eliminated, there were no viable
tumor cellsdetectable using a modified clonogenicassay (data
not shown), confirmingthat tumor cytotoxicity was complete.
Although the target cells were efficiently eliminated by
ADCC, we observed no release of radioactive chromium or
indium during the process. To determine the fate of the un-
released tracer, we incubated radiolabeled tumor cells with
cultured monorytes and antibody for 24 h, then selectively
lysed any remaining target cells with complement. After
ADCC, <2% of the original radionuclide was recoverable
by complement lysis, even though none had been released
during ADCC (Fig. 2 B). All of the sequestered tracer was
recovered when the monocyte monolayer was solubilized with
detergent. In contrast, radionuclide from control target cells
incubated with monorytes but without antibody was >95%
complement releasable(Fig. 2 A). Our interpretation of these
data was that the tracer had been phagocytosed by the mono-
cytes during ADCC, rendering it immune to complement
but releasable by detergent. An alternative explanation of the
data might be that the target antigen had modulated offthe
cell surface during ADCC, thus preventing fixation of com-
plement. Experiments such as the one shown in Fig. 1 B
proved that this was not the case. To determine whether the
uptake ofradionuclide occurred before or after target cell death,
we released the chromium from labeled target cells by freeze-
thawing, then incubated the cell lysate with cultured mono-
cytes. Under these conditions, free radionuclide was not taken
up at all. Therefore, we concluded that the monorytes were
not lysing the target cells extracellularly and subsequently
ingesting the liberated tracer.
Transmission electron micrographs ofcultured monorytes
and tumor cells during ADCC showed intact target cells
within monocyte phagosomes (Fig. 3). To quantitate this
phenomenon, we prelabeled target cells with the fluorochromeFigure 1 .
￿
Disappearance of
tumor-associated antigen during
ADCC by cultured monocytes .
Human monocytes were cultured
for 11 d in rhM-CSF, as described
in Materials and Methods, then
SKMel-1 melanoma target cells
and antitumor antibody (R24)
were added. (A) After 0, 4, 8, and
24 h, the cells were harvested, and
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body 3178 . Monocytes were coun-
terstained with anti-CD14 and
anti-CD11b PE, and the number
of surviving target cells (expressed as a percentage of the starting number of target cells) was determined by flow cytometry . (B) Two-color con-
tour plots of the cells at the start of incubation (0 h), and after 8 h in the presence of opsonizing antibody. After ADCC, the target cell popu-
lation disappeared from region 4, and no population of antigen-negative target cells emerged in region 3. Data are from one of six similar ex-
periments; E/T ratio, 2:1 .
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PKH2, a green-fluorescent vital dye that binds tightly to cell
membranes and shows little transference from cell to cell (10) .
Monocytes were counterstained with anti-CD14/anti-CD11b
PE . DuringADCC, dye-labeled target cells were rapidly taken
up by cultured monocytes, often retaining their shape for a
period of time after phagorytosis (Fig. 4) .
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Figure 2 .
￿
Internalization of 51Cr by cultured monocytes during
ADCC. Human monocytes, cultured as in Fig. 1, were incubated
with 51Cr-labeled neuroblastoma cells (LAN-1), either without (A)
or with (B) antitumor antibody 3178 . Control target cells were in-
cubated without monocytes. After 24 h, the supernatant was removed
for gamma counting, and the cell monolayers were washed to remove
free 5 1Cr. The plates were centrifuged before and after washing to re-
tain nonadherent cells. Residual target cells were lysed with human
complement and additional antibody. Target cells were equally sensi-
tive to lysis by complement, regardless of exposure to antibody
during the 24-h incubation, as demonstrated by the control bars in
both figures. After complement lysis, the monocyte monolayer in B
was solubilized with detergent to release ingested chromium . The
bars show specific release of radionuclide for each successive treat-
ment. Data are from one of four experiments using 51Cr, and two
experiments using "'In, all with similar results ; E/T ratio, 4 :1 .
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Two-color cytofluorometry of PKH2-stained cells (Fig. 5)
demonstrated that during ADCC the target cell population
(region 4) progressively disappeared, while a new popula-
tion ofPKH2+ monocytes emerged . These two populations
represent, respectively, the unphagocytosed and phagocytosed
target cells illustrated in Fig . 4, A andB . Because it was pos-
sible that antibody-coated tumor cells might bind to macro-
phages without undergoing phagorytosis, we also examined
the stained cells under a fluorescence microscope, looking for
the formation ofmonocyte-target cell conjugates . We found
<1% of target cells bound to monocytes after the vigorous
washing steps used in the staining process. The time course
for the disappearance of PKH2-labeled target cells (Fig. 5 C)
was similar to that seen for the elimination of cells bearing
tumor-associated antigen (shown in Fig . 1 A) .
We observed antitumor phagorytosis with a variety ofcell
lines . Table I presents data from representative experiments
using five different human tumor cell lines, andmAbs of the
murine IgG3 and IgG2a andhuman IgG1 subclasses . Phago-
cytosis was measured as uptake of PKH2-labeled target cells,
as shown in Fig. 5 . These data are taken from several experi-
ments using different lots of effector cells and various E/T
ratios. They are included to show that the phenomenon of
phagorytosis is not a restricted one, but are not intended to
provide a comparison of relative sensitivity to ADCC.
Discussion
Several mechanisms of monocyte/macrophage antitumor Cy-
totoxicity have been described . The most extensively studied
of these have been the release ofreactive oxidative intermediates
(11-14), secretion ofTNF (15-17), and elaboration of other
soluble cytotoxic factors (18-21) . Like many human tumor
cell lines (22-24), the target cells used in our assays were rel-
atively insensitive to both oxidative killing and TNF (LDso
for H202, >1,000PM as measured by 51Cr release; LDso for
TNF, >1,000 U/ml as measured by 48-h in vitro prolifera-
tion assay) . In previous studies ofbystander cell killing during
ADCC, we had found no evidence ofany secreted cytotoxic
factor in our system (3) . Thus, we turned to phagorytosis234
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Figure 3 .
￿
Phagocytosis of
antibody-coated tumor cells by
cultured monocytes . Electron
micrographs of cultured monocytes
and melanoma target cells after
4-h co-incubation in the presence
of antibody, as described in Fig. 1 .
(A) Cultured monocytes (bar,
5 um); (B) tumor cells; (C) tumor
cell inside monocyte phagosome;
(D) cytolysis of phagocytized
tumor cell .
Figure 4.
￿
Phagocytosis of fluorochrome-labeled
target cells. Monocytes cultured in rhM-CSF were
incubated for 8 h with neuroblastoma cells and an-
titumor antibody 3F8, as in Fig. 1. The target cells
had been prelabeled with the fluorescent dye PKH2
(green) ; monocytes were counterstained with anti-
CD141anti-CD11b PE (red) . (A) Control, no anti-
body; (B) with antibody.W a
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as a potential mechanism of ADCC by rhM-CSF-cultured
monorytes.
Antibody-directed phagocytosis is an important function
of monorytes and macrophages. Ingestion of opsonized
microorganisms, redcells, andplatelets by macrophages have
all been extensively studied. It is thus somewhat surprising
that the role of phagocytosis in antitumor cytotoxicity has
received relatively little attention. Thephenomenon waswell
described 25 yr ago by Bennett et al. (25, 26), using mouse
peritoneal macrophagesandpolyclonal antisera. However, since
that time, we are aware of only three studiesin the literature
dealing with macrophage phagocytosis of malignant cells
(27-29). Recent excellent and extensive reviews of macro-
phage antitumorcytotoxicity (30, 31) do notmentionphago-
cytosis as a potentialmechanism forADCC, nor does a 1985
workshop report on assays for monocyte cytotoxicity (32).
Target cell
￿
Tumor type
￿
Antibody
LA-N-1 Neuroblastoma 31`8
SKMel-1 Melanoma
￿
ch14.18
LS180 Colon
￿
NRC04
A431
￿
Epidermoid carcinoma
￿
528
SK-BR-3 Breast
￿
528
INCUBATION TIME (h)
Figure 5.
￿
Time course of tumor cell phagocytosis. PKH2-labeled neuroblastoma cells were incubated with cultured monocytes and antibody as
described in Fig. 4, then harvested with EDTA. Monocytes were stained with anti-CD14/anti-CD11b PE. (A) At the start of incubation, region
1 contains the monocyte population and region 4 contains the unphagocytosed target cells. (B) After 24 h, phagocytosed target cells (as pictured
in Fig. 4B) are seen in region 2. (C) Total number of unphagocytosed target cells (squares) and PKH2* monocytes (triangles) over the course of
a 24-h ADCC incubation. These data are from one of four similar experiments; E/T ratio, 2:1. In some experiments, samples were also scored
for the formation of monocyte-target cell conjugates by fluorescence microscopy (<1% of target cells were found passively bound to monocytes).
In the present study, our results support the hypothesis
that phagocytosis of intact target cells is the principal mech-
anism of in vitro antitumor ADCC by rhM-CSF-cultured
monorytes. While it is quitepossible that other, nonphago-
cytic(i.e., extracellular) mechanisms also operate, their con-
tribution would appear to be minor in our system. This is
shown by the isotope release assays, which indicate that few
target cell deaths occur extracellularly, sincevery little radio-
nuclide is released during target cell killing. If tumor cells
were being killed or injured before phagocytosis, we should
expect to see evidence of chromium release, especially since
chromium once liberated from target cells is not taken up
by cultured monorytes.
Tumor cell phagocytosis during ADCC is not arestricted
phenomenon in our system. We observed phagocytosis, as
demonstrated by uptake of fluorescent-labeled target cells, with
Table 1.
￿
Phagocytosis of Various Tumor Cell Targets Using Opsonizing Antibodies o.fDtiferent Human and Murine Subclasses
Fc subclass
￿
E/T
￿
Phagocytosis
Murine IgG3
￿
4:1
￿
92
Human IgG1
￿
2:1
￿
55
Murine IgG3
￿
1:1
￿
44
Murine IgG2a
￿
4:1
￿
89
Murine IgG2a
￿
4:1
￿
65
Human tumor cell lines were labeled with PKH2 dye and incubated for 24 h with cultured monocytes and antitumor antibody, as
described in Materials and Methods. Phagocytosis was quantitated by two-color flow cytometry, using the definitions for phagocytosed
(double positive) and unphagocytosed target cells established in Fig. 5. Percent phagocytosis was calculated as the ratio of phagocytosed tar-
get cells to total target cells. The E/T ratio is a measured value based on the relative number of targets and effectors after the 24-h co-
incubation.a variety of tumor types. Antibodies of the murine IgG2a
and IgG3 subclasses, and a chimeric antibody with a human
IgG1 Fc portion, were all able to direct efficient phagocy-
tosis. Thus far, we have tested 26 cell lines and have seen
antibody-dependent and/or antibody-independent phagocy-
tosis in all of them (manuscripts in preparation) .
We have demonstrated that cytotoxicity mediated by phago-
cytosis cannot be accurately measured by methods that rely
on radionuclide release. In a limited number of experiments,
we have seen some release of thymidine with selected cell
lines, but indium and chromium release have consistently been
negative. Other laboratories have used isotope-release assays
and have reported seeing varying degrees ofcytotoxicity. Several
factors may contribute to the difference between our results
and theirs. First, our system for culturing monocytes produces
large, highly cytotoxic effector cells. With fresh monocytes,
or monocytes cultured underother conditions, phagocytosis
might play a less prominent role. Second, monocytes and mac-
rophages stimulated with certain agents (e.g., lipopolysac-
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